America leads the world in Alzheimer's innovation — but a new op-ed in the Washington Examiner argues that without a serious commitment to deploying those breakthroughs, a geopolitical rival may be beating us where it counts. Read the full piece here →

From the Washington Examiner, by Aiden Buzzetti:

"New polling from the Market Institute and President Donald Trump's pollster Fabrizio Ward finds that an overwhelming 87% of voters believe fighting Alzheimer's should be a priority. Nearly 4 in 5 say they are more likely to support candidates who prioritize better access to Alzheimer's detection, diagnosis, and treatment."

"More than 7 million Americans live with it, and that number is projected to nearly double by 2060. The disease already costs America hundreds of billions annually through welfare, long-term care, lost productivity, and unpaid caregiving."

"New research shows treating patients before symptoms emerge could add approximately one year of life, reduce nursing-home stays by nearly two years, and lower medical spending by about $48,000 per patient."

"China's leaders understand Alzheimer's and dementia as threats to economic growth, workforce participation, and national competitiveness. But America leads the world in creating next-generation Alzheimer's breakthroughs. It should lead the world in deploying them."

Aiden Buzzetti's piece in the Washington Examiner is a timely reminder that American leadership on Alzheimer's cannot stop at innovation — it has to extend to access, early diagnosis, and treatment. Read the full commentary here.

‍